A health economics study using a microsimulation model showed that TissueCypher-guided management is both cost-saving and helps improve patient health outcomes.

Assessing additional spatial and temporal biopsies increased the predictive accuracy, allowing for identification of most future progressors.

Utilizing patient data provided through collaboration with the NCI SEER program (diagnosis 2016-2018) the 31-GEP class results was a statistically significant independent predictor of MSS and can help identiy patients with low risk of death who may potentially forego unnecessary procedures

TissueCypher may be a practical and effective solution to the lack of standardization of expert pathology review of LGD as advocated by all guidelines.

Patient Survery performed in conjunction with Melanoma Research Foundation on patient attitudes towards prognostic testing

To determine the impact of cSCC-GEP test results on management decisions made by dermatologists for cSCC patients.

TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.

11-member Melanoma Evolving Diagnostic Technologies Integration Group (MEDTIG) derived an algorithmic approach to systematically facilitate incorporating these technologies into the evaluation and management of suspicious PSLs.

Definitive diagnoses by dermatopathologists in challenging melanocytic lesions increased by 57% by incorporating the results of 23-GEP

Over 50% of newly diagnosed cutaneous squamous cell carcinoma (cSCC) lesions occur in the head and neck (cSCC‐HN), and metastasis to nodal basins in this region further complicates surgical and adjuvant treatment.

Multicenter study shows clear and significant separation of risk between Class 1 and Class 2 result for DFS,DMFS, MSS, OS using Kaplan-Maier analysis.